Cited by 177Antifungal resistance and susceptibilityAntibiotics Pharmacokinetics and EfficacyFungal Infections and Studies

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis

Open access

Andes, D., Marchillo, K., Conklin, R., Krishna, Gopal, Ezzet, Farkad, Cacciapuoti, Anthony, Loebenberg, David·2004·Antimicrobial Agents and Chemotherapy

DOI 10.1128/aac.48.1.137-142.2004PMC PMC310197

Open this paper in CoChat — free account

Abstract

Previous in vivo studies have characterized the pharmacodynamic characteristics of two triazole compounds, fluconazole and ravuconazole. These investigations demonstrated that the 24-h area under the concentration-time curve (AUC)/MIC ratio is the critical pharmacokinetic-pharmacodynamic (PK-PD) parameter associated with treatment efficacy. Further analysis demonstrated that a free-drug triazole 24-h AUC/MIC ratio of 20 to 25 was predictive of treatment success in both experimental models and clinical trials. We used a neutropenic murine model of disseminated Candida albicans infection to similarly characterize the time course activity of the new triazole, posaconazole. The PK-PD parameters (percent time above MIC, AUC/MIC ratio, and peak serum drug level/MIC ratio) were correlated with in vivo efficacy, as measured by organism number in kidney cultures after 48 h of therapy. Kinetics and protein binding following oral posaconazole dosing were performed in neutropenic infected mice. Peak levels and AUC from 0 h to ∞ values were nonlinear over the 16-fold dose range studied. Serum drug elimination half-life ranged from 12.0 to 17.7 h. Protein binding was 99%. Single dose postantifungal effect studies demonstrated prolonged suppression of organism regrowth after serum posaconazole levels had fallen below the MIC. Treatment efficacy with the four dosing intervals studied was similar, supporting the AUC/MIC ratio as the PK-PD parameter predictive of efficacy. Nonlinear regression analysis also suggested that the AUC/MIC ratio was strongly predictive of treatment outcomes (AUC/MIC ratio R 2 = 83%; peak serum drug/MIC ratio R 2 = 85%; time that serum levels of posaconazole remained above the MIC R 2 = 65%). Similar studies were conducted with 11 additional C. albicans isolates with various posaconazole susceptibilities (MIC, 0.015 to 0.12 μg/ml) to determine if a similar 24-h AUC/MIC ratio was associated with efficacy. The posaconazole free-drug AUC/MIC ratios were similar for all of the organisms studied (6.12 to 26.7, mean ± SD = 16.9 ± 7.8, P value, 0.42). These free-drug AUC/MIC ratios are similar to those observed for other triazoles in this model.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1128/aac.48.1.137-142.2004

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736
State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Antibiotics in Laboratory Medicine.
Lorian, V. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-4-653_4 · Cited by 2,809
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S. R., Leggett, J., Turnidge, J. D., Ebert, S. C., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720
Acute otitis media: management and surveillance in an era of pneumococcal resistance-a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group
Dowell, S. F., Butler, J. C., Giebink, G. S., Jacobs, M. R., Jernigan, D. B., Musher, D. M., Rakowsky, A., & Schwartz, B. (1999) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199901000-00002 · Cited by 505
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
Craig, W. A., & Andes, D. R. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00015 · Cited by 438
Self-citation
Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis
Redding, S., Smith, J., Farinacci, G., Rinaldi, M., Fothergill, A., Rhine-Chalberg, J., & Pfaller, M. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.2.240 · Cited by 269

Show all 26 references

Research works printed but not linked: 2

Craig W. A. and B. Suh. 1996. Protein binding and the antimicrobial effects: methods for the determination of protein binding p. 367-402. In V. Lorian (ed.) Antibiotics in laboratory medicine 4th ed. Williams and Wilkins Baltimore Md.
Kunin, C. M. 1965. The importance of serum protein binding in determining antimicrobial activity and concentration in serum. Clin. Pharmacol. Ther.7:168-179.

Sorted by citations

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
Ashbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt508 · Cited by 721
Recent Advances in the Management of Mucormycosis: From Bench to Bedside
Spellberg, B. J., Walsh, T. J., Kontoyiannis, D. P., Edwards, J. E., & Ibrahim, A. S. (2009) · Clinical Infectious Diseases · doi:10.1086/599105 · Cited by 548
Antifungal therapeutic drug monitoring: established and emerging indications
Andes, D., Pascual, A., & Marchetti, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00705-08 · Cited by 490
Self-citation
Pharmacokinetic/Pharmacodynamic Profile of Voriconazole
Theuretzbacher, U., Ihle, F., & Derendorf, H. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645070-00002 · Cited by 482
Pharmacokinetic/Pharmacodynamic Profile of Posaconazole
Li, Y., Theuretzbacher, U., Clancy, C. J., Nguyen, M. H., & Derendorf, H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319340-000000000-00000 · Cited by 452
Current Concepts in Antifungal Pharmacology
Lewis, R. E. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0247 · Cited by 391
Drug nanocrystals: in vivo performances.
Gao, L., Liu, G., Ma, J., Wang, X., Zhou, L., & Li, X. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.013 · Cited by 347
Pharmacology of Systemic Antifungal Agents
Ashley, E. S. D., Lewis, R. E., Lewis, J. S., Martin, C. A., & Andes, D. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504492 · Cited by 317
Self-citation
Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
Arastehfar, A. A., Gabaldón, T., Garcia‐Rubio, R., Jenks, J. D., Hoenigl, M., Salzer, H. J. F., İlkit, M., Lass‐Flörl, C., & Perlin, D. S. (2020) · Antibiotics · doi:10.3390/antibiotics9120877 · Cited by 302
Triazole Antifungal Agents in Invasive Fungal Infections
Lass‐Flörl, C. (2011) · Drugs · doi:10.2165/11596540-000000000-00000 · Cited by 276
Zygomycosis (mucormycosis): emerging clinical importance and new treatments
Greenberg, R. N., Scott, L. J., Vaughn, H. H., & Ribes, J. A. (2004) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200412000-00003 · Cited by 257
In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species
Andes, D., Diekema, D. J., Pfaller, M. A., Bohrmuller, J., Marchillo, K., & Lepak, A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01584-09 · Cited by 226
Self-citation
Application of Drug Nanocrystal Technologies on Oral Drug Delivery of Poorly Soluble Drugs
Gao, L., Liu, G., Ma, J., Wang, X., Zhou, L. F., Li, X., & Wang, F. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0889-z · Cited by 227
Posaconazole: A Broad-Spectrum Triazole Antifungal Agent
Nagappan, V., & Deresinski, S. C. (2007) · Clinical Infectious Diseases · doi:10.1086/523576 · Cited by 223
Candida Urinary Tract Infections—Treatment
Fisher, J. F., Sobel, J. D., Kauffman, C. A., & Newman, C. A. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir112 · Cited by 219
Pharmacokinetics and Pharmacodynamics of Posaconazole
Chen, L., Krekels, E. H. J., Verweij, P. E., Buil, J. B., Knibbe, C. A. J., & Brüggemann, R. J. M. (2020) · Drugs · doi:10.1007/s40265-020-01306-y · Cited by 185
Fluconazole MIC and the Fluconazole Dose/MIC Ratio Correlate with Therapeutic Response among Patients with Candidemia
Clancy, C. J., Yu, V. L., Morris, A. J., Snydman, D. R., & Nguyen, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3171-3177.2005 · Cited by 175
New and emerging treatments for fungal infections
Pasqualotto, A. C., & Denning, D. W. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm428 · Cited by 173
Combination Therapy for Mucormycosis: Why, What, and How?
Spellberg, B. J., Ibrahim, A. S., Roilides, E., Lewis, R. E., Lortholary, O., Petrikkos, G. L., Kontoyiannis, D. P., & Walsh, T. J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir885 · Cited by 168
Association of Fluconazole Area under the Concentration-Time Curve/MIC and Dose/MIC Ratios with Mortality in Nonneutropenic Patients with Candidemia
Pai, M. P., Turpin, R. S., & Garey, K. W. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00474-06 · Cited by 160
Posaconazole
Keating, G. M. (2005) · Drugs · doi:10.2165/00003495-200565110-00007 · Cited by 158
Therapeutic Drug Monitoring of Antifungals: Pharmacokinetic and Pharmacodynamic Considerations
Smith, J., & Andes, D. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318167d0e0 · Cited by 156
Self-citation
Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat
Rabinow, B. E., Kipp, J., Papadopoulos, P., Wong, J., Glosson, J., Gass, J. H., Sun, C.-S., Wielgos, T., White, R., Cook, C. S., et al. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.02.030 · Cited by 154
Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug Monitoring
Dolton, M. J., Ray, J. E., Marriott, D. J. E., & McLachlan, A. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05900-11 · Cited by 148
Therapeutic drug monitoring for triazoles
Hope, W. W., Billaud, E. M., Lestner, J. M., & Denning, D. W. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283184611 · Cited by 141
Pharmacokinetics of Antibacterial Agents in the CSF of Children and Adolescents
Sullins, A. K., & Abdel‐Rahman, S. M. (2013) · Pediatric Drugs · doi:10.1007/s40272-013-0017-5 · Cited by 140
Antifungal serum concentration monitoring: an update
Goodwin, M. L., & Drew, R. H. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm389 · Cited by 136
Posaconazole: An extended-spectrum triazole antifungal agent
SCHILLER, D., & Fung, H. B. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.015 · Cited by 135
Antifungal Pharmacokinetics and Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134
Self-citation
Modelling time–kill studies to discern the pharmacodynamics of meropenem
Tam, V. H., Schilling, A. N., & Nikolaou, M. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki086 · Cited by 134
Pharmacokinetics and Pharmacodynamics of Antifungals
Andes, D. R. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.06.007 · Cited by 113
Self-citation
Posaconazole: clinical pharmacology and potential for management of fungal infections
Groll, A. H., & Walsh, T. J. (2005) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.3.4.467 · Cited by 114
Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A Gene
Mavridou, E., Brüggemann, R. J. M., Melchers, W. J. G., Mouton, J. W., & Verweij, P. E. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00931-09 · Cited by 112
Safety of triazole antifungal drugs in patients with cancer
Cronin, S. M., & Chandrasekar, P. H. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp464 · Cited by 109
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent
Rybak, J. M., Marx, K. R., Nishimoto, A. T., & Rogers, P. D. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1652 · Cited by 101
In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.
Warn, P. A., Sharp, J., & Denning, D. W. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki399 · Cited by 93
Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection
Chhun, S., Rey, E., Tran, A., Lortholary, O., Pons, G., & Jullien, V. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2007.01.021 · Cited by 91
Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect
Warn, P. A., Sharp, J., Parmar, A., Majithiya, J. B., Denning, D. W., & Hope, W. W. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01601-08 · Cited by 87
Pharmacokinetics/pharmacodynamics of echinocandins
Theuretzbacher, U. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1228-z · Cited by 86
Intrapulmonary Pharmacokinetics and Pharmacodynamics of Posaconazole at Steady State in Healthy Subjects
Conte, J. E., Golden, J. A., Krishna, G., McIver, M., Little, E., & Zurlinden, E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00663-08 · Cited by 84
Self-citation
Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future
Rayner, C. R., Smith, P. F., Andes, D. R., Andrews, K. A., Derendorf, H., Friberg, L. E., Hanna, D. L., Lepak, A. J., Mills, E. J., Polasek, T. M., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2198 · Cited by 82
Self-citation
Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus
Warn, P. A., Sharp, J., Mosquera, J., Spickermann, J., Schmitt‐Hoffmann, A. H., Heep, M., & Denning, D. W. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl396 · Cited by 77
A Reference Laboratory Experience of Clinically Achievable Voriconazole, Posaconazole, and Itraconazole Concentrations within the Bloodstream and Cerebral Spinal Fluid
Wiederhold, N. P., Pennick, G. J., Dorsey, S. A., Furmaga, W. B., Lewis, J. S., Patterson, T. F., Sutton, D. A., & Fothergill, A. W. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01558-13 · Cited by 76
Posaconazole Pharmacodynamic Target Determination against Wild-Type and Cyp51 Mutant Isolates of Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis
Lepak, A. J., Marchillo, K., VanHecker, J., & Andes, D. R. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01279-12 · Cited by 71
Self-citation
Posaconazole Exhibits In Vitro and In Vivo Synergistic Antifungal Activity with Caspofungin or FK506 against Candida albicans
Chen, Y., Lehman, V. N., Averette, A. F., Perfect, J. R., & Heitman, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057672 · Cited by 69
In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model
Zhao, M., Lepak, A. J., VanScoy, B., Bader, J. C., Marchillo, K., Vanhecker, J., Ambrose, P. G., & Andes, D. R. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02542-17 · Cited by 68
Self-citation
Isavuconazole Pharmacodynamic Target Determination for Candida Species in an In Vivo Murine Disseminated Candidiasis Model
Lepak, A. J., Marchillo, K., VanHecker, J., Diekema, D. J., & Andes, D. R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01354-13 · Cited by 64
Self-citation
Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting
Lepak, A., & Andes, D. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2010.11.001 · Cited by 62
Self-citation
Candiduria: Evidence-based approach to management, are we there yet?
Alfouzan, W. A., & Dhar, R. (2017) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2017.04.005 · Cited by 62
Development, Validation, and Routine Application of a High-Performance Liquid Chromatography Method Coupled with a Single Mass Detector for Quantification of Itraconazole, Voriconazole, and Posaconazole in Human Plasma
Baietto, L., D’Avolio, A., Ventimiglia, G., Rosa, F. G. D., Siccardi, M., Simiele, M., Sciandra, M., & Perri, G. D. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01807-09 · Cited by 58
Green synthesis and biological evaluation of some novel azoles as antimicrobial agents
Shelke, S. N., Mhaske, G. R., Gadakh, S., & Gill, C. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.10.111 · Cited by 54
Single-Dose Pharmacokinetics of Intravenous Itraconazole and Hydroxypropyl-β-Cyclodextrin in Infants, Children, and Adolescents
Abdel‐Rahman, S. M., Jacobs, R. F., Massarella, J. W., Kauffman, R. E., Bradley, J. S., Kimko, H. C., Kearns, G. L., Shalayda, K., Curtin, C. R., Maldonado, S., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00297-07 · Cited by 54
Posaconazole: An Oral Triazole with an Extended Spectrum of Activity
Rachwalski, E. J., Wieczorkiewicz, J. T., & Scheetz, M. H. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1l005 · Cited by 53
Comparative Pharmacodynamics of Posaconazole in Neutropenic Murine Models of Invasive Pulmonary Aspergillosis and Mucormycosis
Lewis, R. E., Albert, N. D., & Kontoyiannis, D. P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03569-14 · Cited by 51
APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis
Zhao, M., Lepak, A. J., Marchillo, K., VanHecker, J., Sánchez, H., Ambrose, P. G., & Andes, D. R. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02372-18 · Cited by 51
Self-citation
Pharmacokinetics and Pharmacodynamics of Antifungals in Children and their Clinical Implications
Stockmann, C. R., Constance, J. E., Roberts, J. K., Olson, J. A., Doby, E. H., Ampofo, K., Stiers, J., Spigarelli, M. G., & Sherwin, C. M. T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0139-0 · Cited by 51
Pharmacokinetics of voriconazole after oral and intravenous administration to horses
Davis, J. L., Salmon, J. H., & Papich, M. G. (2006) · American Journal of Veterinary Research · doi:10.2460/ajvr.67.6.1070 · Cited by 49
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside
Hope, W. W., & Drusano, G. L. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02913.x · Cited by 48
Combination Therapy of Advanced Invasive Pulmonary Aspergillosis in Transiently Neutropenic Rats Using Human Pharmacokinetic Equivalent Doses of Voriconazole and Anidulafungin
van de Sande, W. W. J., Mathôt, R. A. A., ten Kate, M. T., van Vianen, W., Tavakol, M., Rijnders, B. J. A., & Bakker‐Woudenberg, I. A. J. M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01556-08 · Cited by 45
Clinical utility of antifungal pharmacokinetics and pharmacodynamics
Andes, D. R. (2004) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200412000-00005 · Cited by 45
Self-citation
ASP2397 Is a Novel Natural Compound That Exhibits Rapid and Potent Fungicidal Activity against Aspergillus Species through a Specific Transporter
Nakamura, I., Ohsumi, K., Takeda, S., Katsumata, K., Matsumoto, S., 赤松, 総., Mitori, H., & Nakai, T. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02689-18 · Cited by 44
Posaconazole: A new oral antifungal agent with an expanded spectrum of activity
Morris, M. I. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070532 · Cited by 44
Steady-State Intrapulmonary Pharmacokinetics and Pharmacodynamics of Posaconazole in Lung Transplant Recipients
Conte, J. E., DeVoe, C., Little, E., & Golden, J. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01396-09 · Cited by 43
Antimicrobial Dosing in Acute Renal Replacement
Fissell, W. H. (2012) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2012.10.004 · Cited by 42
Overview of antifungal dosing in invasive candidiasis
Pea, F., & Lewis, R. E. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx447 · Cited by 43
In vitro pharmacodynamic evaluation of antiviral medicinal plants using a vector-based assay technique
Esimone, C. O., Grünwald, T., Wildner, O., Nchinda, G., Tippler, B. G., Proksch, P., & Überla, K. (2005) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2005.02732.x · Cited by 42
Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via In Vivo Pharmacodynamic Evaluation against Candida glabrata with and without fks Mutations
Lepak, A. J., Castanheira, M., Diekema, D. J., Pfaller, M. A., & Andes, D. R. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-12 · Cited by 42
Self-citation
Intrapulmonary Pharmacokinetics and Pharmacodynamics of Itraconazole and 14-Hydroxyitraconazole at Steady State
Conte, J. E., Golden, J. A., Kipps, J., McIver, M., & Zurlinden, E. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3823-3827.2004 · Cited by 41
PK-PD Integration Modeling and Cutoff Value of Florfenicol against Streptococcus suis in Pigs
Lei, Z., Liu, Q., Yang, S., Yang, B., Khaliq, H., Li, K., Ahmed, S., Sajid, A., Zhang, B., Pin, C., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00002 · Cited by 40
Pharmacodynamic implications for use of antifungal agents
Lewis, R. E. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.05.004 · Cited by 38
Posaconazole: when and how? The clinician’s view
Katragkou, A., Tsikopoulou, F., Roilides, E., & Zaoutis, T. E. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02061.x · Cited by 36
Mechanism-Based Pharmacokinetic-Pharmacodynamic Models of In Vitro Fungistatic and Fungicidal Effects against Candida albicans
Venisse, N., Grégoire, N., Marliat, M., & Couet, W. R. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01030-07 · Cited by 36
Validation of rapid and simple LC–MS/MS method for determination of voriconazole in rat plasma
de Araújo, B. V., Conrado, D. J., Palma, E. C., & Costa, T. D. (2007) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2007.03.026 · Cited by 36
Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients
Sime, F. B., Byrne, C. J., Parker, S. L., Stuart, J., Butler, J., Starr, T., Pandey, S., Wallis, S. C., Lipman, J., & Roberts, J. A. (2019) · Critical Care · doi:10.1186/s13054-019-2483-9 · Cited by 34
Impact ofIn VivoTriazole and Echinocandin Combination Therapy for Invasive Pulmonary Aspergillosis: Enhanced Efficacy againstCyp51Mutant Isolates
Lepak, A. J., Marchillo, K., VanHecker, J., & Andes, D. R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00833-13 · Cited by 33
Self-citation
Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections
Groll, A. H., & Walsh, T. J. (2006) · Mycoses · doi:10.1111/j.1439-0507.2006.01296.x · Cited by 33
Posaconazole: The Case for Therapeutic Drug Monitoring
Howard, S. J., Felton, T., Gómez‐López, A., & Hope, W. W. (2011) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31823cdeac · Cited by 32
Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation?
Baracaldo-Santamaría, D., Cala-García, J., Medina-Rincón, G. J., Rojas-Rodríguez, L. C., & Calderón‐Ospina, C. (2022) · Antibiotics · doi:10.3390/antibiotics11050645 · Cited by 35
Posaconazole in Human Serum: a Greater Pharmacodynamic Effect than Predicted by the Non-Protein-Bound Serum Concentration
Lignell, A., Löwdin, E., Cars, O., Chryssanthou, E., & Sjölin, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01671-10 · Cited by 31
Co‐administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed‐released tablets in adult patients with haematological malignancies
Cojutti, P. G., Candoni, A., Lazzarotto, D., Rabassi, N., Fanin, R., Hope, W. W., & Pea, F. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13707 · Cited by 31
New agents for invasive mycoses in children
Antachopoulos, C., & Walsh, T. J. (2005) · Current Opinion in Pediatrics · doi:10.1097/01.mop.0000150630.83442.e1 · Cited by 31
Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations
Märtson, A., Veringa, A., van den Heuvel, E. R., Bakker, M., Touw, D. J., van der Werf, T. S., Span, L. F. R., & Alffenaar, J. C. (2019) · Mycoses · doi:10.1111/myc.12948 · Cited by 30
Mathematical modelling response of Pseudomonas aeruginosa to meropenem
Tam, V. H., Schilling, A. N., Poole, K., & Nikolaou, M. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm370 · Cited by 30
Interaction between Posaconazole and Caspofungin in Concomitant Treatment of Mice with Systemic Aspergillus Infection
Cacciapuoti, A. F., Halpern, J., Mendrick, C. A., Norris, C., Patel, R. J., & Loebenberg, D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00829-05 · Cited by 27
Self-citation
Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections
Neofytos, D. (2010) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s6321 · Cited by 26
Development and validation of a high-performance liquid chromatography assay for posaconazole utilizing solid-phase extraction
Störzinger, D., Swoboda, S., Lichtenstern, C., Müller, C., Weigand, M. A., & Hoppe‐Tichy, T. (2008) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2008.338 · Cited by 26
Interaction between Posaconazole and Amphotericin B in Concomitant Treatment against Candida albicans In Vivo
Cacciapuoti, A. F., Gurnani, M., Halpern, J., Norris, C., Patel, R. J., & Loebenberg, D. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.638-642.2005 · Cited by 26
Self-citation
Efficacy and Pharmacodynamics of Flucytosine Monotherapy in a Nonneutropenic Murine Model of Invasive Aspergillosis
Dorsthorst, D. T. A. T., Verweij, P. E., Meis, J. F. G. M., & Mouton, J. W. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.10.4220-4226.2005 · Cited by 25
Therapeutic drug monitoring of antimicrobials
Balakrishnan, I., & Shorten, R. J. (2015) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563215618981 · Cited by 24
Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
Sime, F. B., Stuart, J., Butler, J., Starr, T., Wallis, S. C., Pandey, S., Lipman, J., & Roberts, J. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00242-18 · Cited by 23
Free renal levels of voriconazole determined by microdialysis in healthy and Candida sp.-infected Wistar rats
de Araújo, B. V., da Silva, C. F., Haas, S. E., & Costa, T. D. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.08.020 · Cited by 23
Antifungal PK/PD Considerations in Fungal Pulmonary Infections
Lepak, A. J., & Andes, D. R. (2011) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0031-1295726 · Cited by 23
Self-citation
Farmacología de los azoles
Perea, J. R. A., Garcia-Quetglas, E., & Sádaba, B. (2007) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(07)70047-5 · Cited by 23
Formulation and optimization of transferrin-modified genistein nanocrystals: In vitro anti-cancer assessment and pharmacokinetic evaluation
Iqbal, F. M., Rodríguez‐Nogales, C., Boulens, N., & Delié, F. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124863 · Cited by 23
The Susceptibility Patterns of Candida Species Isolated From Urine Samples to Posaconazole and Caspofungin
Mahmoudabadi, A. Z., Rezaei‐Matehkolaei, A., & Ghanavati, F. (2015) · Jundishapur Journal of Microbiology · doi:10.5812/jjm.24298 · Cited by 22
Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality
Hope, W. W., Drusano, G. L., & Rex, J. H. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw298 · Cited by 21
Antifungal activity of posaconazole and granulocyte colony‐stimulating factor in the treatment of disseminated zygomycosis (mucormycosis) in a neutropaenic murine model
Saoulidis, S., Simitsopoulou, M., Dalakiouridou, M., Walsh, T. J., Wheat, L. J., Papaioannidou, P., & Roilides, E. (2010) · Mycoses · doi:10.1111/j.1439-0507.2010.01958.x · Cited by 21
Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance
Andes, D. R. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.06.002 · Cited by 19
Self-citation
Intrapulmonary Posaconazole Penetration at the Infection Site in an Immunosuppressed Murine Model of Invasive Pulmonary Aspergillosis Receiving Oral Prophylactic Regimens
Seyedmousavi, S., Brüggemann, R. J. M., Melchers, W. J. G., Verweij, P. E., & Mouton, J. W. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00053-14 · Cited by 17
Are In Vitro Susceptibilities to Azole Antifungals Predictive of Clinical Outcome in the Treatment of Candidemia?
Patel, T. S., Carver, P. L., & Eschenauer, G. A. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01072-18 · Cited by 17

Authors: Andes, D., Marchillo, K., Conklin, R., Krishna, G., Ezzet, F., Cacciapuoti, A., & Loebenberg, D.
Affiliations: University of Wisconsin System (US)
William S. Middleton Memorial Veterans Hospital (US)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
ORCID: Andes, D.
Krishna, Gopal
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 2004-01
Volume: 48
Issue: 1
Pages: 137-142
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.48.1.137-142.2004
PMC: PMC310197
OpenAlex: W2126064588
Cited by: 177
References: 26
Citations by year: 2026: 1 · 2025: 7 · 2024: 5 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 6 · 2019: 5 · 2018: 8 · 2017: 4 · 2016: 5 · 2015: 8 · 2014: 8 · 2013: 12 · 2012: 9
FWCI: 4.47
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Keywords: posaconazole, triazole antifungals, pharmacodynamics, pharmacokinetics, systemic candidiasis, Candida albicans, AUC/MIC ratio, neutropenic mice, free drug concentration, drug-protein binding, elimination half-life, fluconazole, ravuconazole, treatment efficacy prediction, nonlinear pharmacokinetics
MeSH terms: Animals, Antifungal Agents, Candida albicans, Candidiasis, Dose-Response Relationship, Drug, Female, Mice, Inbred ICR, Microbial Sensitivity Tests, Neutropenia, Triazoles, Colony Count, Microbial, Area Under Curve, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks